Abstract steroids 4 and the levels are not modulated by bronchodilator therapy. 5 However, in asthmatic Background -Eosinophils in induced sputum and exhaled nitric oxide (NO) are subjects receiving inhaled corticosteroids the levels are reduced. 6 This suggests that exhaled currently used as non-invasive markers in the assessment of airway inflammation in NO may be used as a surrogate marker of airway inflammation. asthma. As both sputum eosinophils (%) and exhaled NO are raised in asthmatic
The aim of our study was to examine the −0.40). Conclusion -The correlation between ex-relationship between exhaled NO and other non-invasive markers of inflammation, inhaled NO and PC 20 suggests that exhaled NO or the mechanisms leading to its in-cluding the number of eosinophils, the amount of ECP in induced sputum, and BHR, and also crease may contribute to airway hyperresponsiveness in asthma. Furthermore, its relationship with % predicted FEV 1 . Such a correlation would allow us to evaluate the the relationship between sputum eosinophils (%), exhaled NO, and PC 20 high-clinical utility of exhaled NO and its potential as a surrogate marker of airway inflammation light the potential use of eosinophils (%) in induced sputum and exhaled NO to in asthma. monitor the severity of asthma.

Thirty five atopic asthmatic patients who were using inhaled 2 agonist alone were studied. All The clinical management of asthma relies on
Department of
monitoring lung function and symptoms. How-of them had stable asthma which was defined as Thoracic Medicine, National Heart and ever, airway inflammation may be present in no changes in asthmatic symptoms and asthma Lung Institute, asthmatic patients whose lung function is nor-medications in the preceding three months. All Imperial College, mal and clinically well controlled, 1 suggesting had a history of wheezing and chest tightness,
London SW3 6LY, UK
A Jatakanon that these measures may not be sensitive were previously diagnosed by a physician as Inflammation in the airways may be reflected ml, and were using inhaled 2 agonists alone in order to control asthma. Exclusion criteria by the levels of nitric oxide (NO) in exhaled       After recovery subjects were instructed to wash This was a cross sectional study. Patients were not allowed to use inhaled 2 agonist for at their mouths thoroughly with water and 3.5% saline at room temperature nebulised via an least six hours before coming to the laboratory. On arrival, all were questioned about their ultrasonic nebuliser (DeVilbiss Co, Heston, UK) at maximum output was then inhaled. asthmatic symptoms and the average requirement of rescue 2 agonist used daily within The subjects were instructed to cough deeply after five and three minute intervals thereafter. the previous three months. Exhaled NO, spirometric values, methacholine challenge test and The total induction time was 15 minutes.
Mouth washing between and before each cough sputum induction were then measured. Sputum induction was performed 15 minutes after was encouraged in order to minimise salivary contamination. The initial sample from the first patients recovered from methacholine challenge test. The patients were required to record cough was discarded. Induced sputum was collected into a 50ml polypropylene tube kept on diary cards for seven days (1) peak flow rates in the morning and evening (best of three) at 4°C and processed within two hours.
Spirometric tests were repeated after the spuusing a mini-Wright peak flow meter, (2) symptom scores (asthma during the day, asthma tum induction. If FEV 1 had dropped below 15% of the post-salbutamol value the subject during the night, and early morning tightness, scored 0-3 for each item), and (3) the number was required to stay until it had returned to the baseline value. of puffs of rescue 2 agonist required daily. Twelve patients performed a second sputum For sputum processing 2ml Hank's balanced salt solution (HBSS) containing 1% dithioinduction one week after the first to evaluate the effect of methacholine on the cell profile threitol (DTT) (Sigma Chemicals, Poole, UK) was added, vortexed, and repeatedly aspirated and ECP levels of the induced sputum.
at room temperature until the sputum was homogenised. The sputum volume was then recorded. Samples were then further diluted    End-exhaled NO was measured by a chemi-with HBSS up to 10ml, vortexed briefly and centrifuged at 400g for 10 minutes at 4°C. luminescence analyser (Model LR2000, Logan Research, Rochester, UK) using the method
The supernatant fluid was kept at −70°C for subsequent assay for ECP. The cell pellet described by Kharitonov et al. 15 In brief, subjects exhaled slowly with an exhalation flow of was resuspended. Total cell count was performed on a haemocytometer using Kimura 5-6 l/min from total lung capacity over 30-40s through a mouthpiece. NO was sampled from stain. An adequate specimen was defined as one having a number of squamous epithelial a side arm attached to the mouthpiece. The mean value was taken from the point cor-cells less than 50% of the inflammatory cells.
Slides were then prepared using a cytospin responding to the plateau of end-exhaled CO 2 reading (5-6% CO 2 ), representing the lower (Shandon, Runcorn, UK) and stained with May-Grunwald-Giemsa for differential cell respiratory tract sample. Results of the analyses were computed and graphically displayed on a counts which were performed by an observer blind to the clinical characteristics of the subplot of NO and CO 2 concentrations, pressure, and flow against time.
jects. At least two slides were used for counting and at least 300 inflammatory cells were counted in each slide.   FEV 1 and FVC were measured with a dry spirometer (Vitalograph Ltd, Buckingham, UK) and the best value of the three manoeuvres was expressed as percentage of predicted value.   The concentration of ECP was measured by radioimmunoassay (Pharmacia & Upjohn Diagnostics, Uppsala, Sweden). Reproduc-  PC 20 was measured by inhalation methacholine ibility of the assay was good with a coefficient of variation of <8%. The detection limit of the challenge with doubling concentrations of methacholine (0.06-32mg/ml) delivered by assay was <2mg/l. dosimeter (Mefar, Bovezzo, Italy) with an output of 100 l. The aerosols were inhaled at tidal breathing with the patient wearing a noseclip. A total of five inhalations of each concentration was administered (inhalation time one second,  
Log transformed values of PC 20 were used breath holding time six seconds) and FEV 1 was measured two minutes after the last inhalation for analysis. The mean values of peak flow variability (amplitude % max) and total sympuntil there was a fall in FEV 1 of 20% compared with the control inhalation (0.9% saline so-tom scores were averaged from the seven day records. Correlations were determined using lution) or until the maximal concentration was inhaled. The PC 20 value was calculated by Spearman rank correlation. A paired sample t test was used to analyse the effect of methainterpolation of the logarithmic dose-response curve. Subjects were given two puffs (200 g) choline on sputum inflammatory cell profiles and ECP concentrations, a p value of <0.05 of salbutamol by a metered dose inhaler following the methacholine challenge test.
being considered significant.
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Figure 2 Correlation between exhaled NO and sputum eosinophils (%).
TCC=total cell count; ECP=eosinophil cationic protein.
capacity to produce NO than the constitutive form. Such a large amount of NO has been reported to result in suppression of Th1 cells and a concomitant reduction in the level of IFN , leading to a proliferation of Th2 cells. Th2 cells then produce several cytokines including IL-5 which is important in the recruitment of eosinophils into the airways. 22 . There is evidence to suggest that PC 20 relates closely to the severity of asthma and the need for treatment.
14 The wide range of PC 20 in mild asthma may limit its use as a sensitive marker of airway inflammation. Nevertheless, we have demonstrated a relationship between sputum eosinophils with PC 20 over a wide range. This wide range may indicate that a varying degree clinical severity as judged by spirometric tests, peak flow variability, and symptoms is similar.
Monitoring of eosinophils in sputum may also be useful as their numbers reflect the extent  There were significant correlations between of airway inflammation. 7 8 However, eosinophil numbers in sputum can also vary widely in exhaled NO and PC 20 (r=−0.64, p<0.001, fig  1) , exhaled NO and sputum eosinophils (%) patients with the same clinical severity of asthma. This suggests that estimation of the (r=0.48, p=0.003, fig 2) , sputum eosinophils (%) and PC 20 (r=−0.40, p=0.02, fig 3) , and extent of airway inflammation should not be based on either PC 20 or sputum eosinophil sputum eosinophils and ECP levels (r=0.41, p=0.01, fig 4) . No significant relationships numbers alone. Furthermore, their relationship with exhaled NO indicates that these markers were found between exhaled NO, sputum eosinophils (%), sputum ECP, or PC 20 and may complement each other in determining asthma severity in patients using inhaled 2 FEV 1 , peak flow variability or symptom scores.
agonists alone. The great advantage of exhaled NO is that the measurement is completely non-invasive, Discussion A significant correlation was found between it can be performed repeatedly, and it can be used in children and patients with severe airflow exhaled NO, PC 20 , and sputum levels of eosinophils. These relationships suggest that NO obstruction where more invasive techniques are not possible. 23 The measurement is not specific, may be useful as a marker of airway inflammation in asthma, as NO itself -or the however, as exhaled NO is also increased in inflammation due to bronchiectasis and resmechanisms resulting in its increase -may contribute to airway inflammation in asthma.
piratory tract infections. This means that serial measurements in individual patients could be There is evidence to suggest that NO itself may contribute to airway hyperresponsiveness more useful than single measurements. Furthermore, exhaled NO does not appear to be a or inflammation. At high concentrations NO may increase airway oedema since it is a potent good marker of airway inflammation in patients with steroid-dependent asthma (Jatakanon et vasodilator and increases plasma exudation from airway vessels. 16 Furthermore, an animal al, unpublished data).
A relationship between eosinophils (%) or model of asthmatic inflammation indicates that NO may increase airway inflammation by en-ECP and percentage predicted FEV 1 or PC 20 has been found previously. [7] [8] [9] A relationship hancing the recruitment of eosinophils into the airways. 17 Internal formation of NO may result between sputum eosinophils and PC 20 has also been shown in our study but we could not in the formation of peroxynitrite through interaction with superoxide anions. 18 Peroxynitrite detect a correlation between the number of eosinophils or the amount of ECP in induced induces airway hyperresponsiveness in guinea pigs. 19 However, in two previous studies there sputum and FEV 1 . This may in part be due to the narrow range of FEV 1 in our patients, and was no apparent correlation between exhaled NO and PC 20 .
20 21 Failure to demonstrate such may also explain the weak relationship between sputum eosinophils and ECP levels as most of a relationship could have been due to either a small sample size or narrow ranges of the levels our patients had mild asthma and therefore had low levels of ECP in induced sputum. of exhaled NO and PC 20 measured, or both. 
